# Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

> **NCT07628504** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 420 (estimated)

## Conditions studied

- Adjuvant Drug Therapy

## Interventions

- **DRUG:** Sacituzumab Tirumotecan (sac-TMT)
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07628504
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2030-03-30
- **Final completion:** 2035-03-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628504, "Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07628504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*